PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM)
BOSTON, Aug. 17, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, has been named Company of the Year for the Pharmaceutical Industry in The Eighth Annual International Business Awards, the only global, all-encompassing business awards program honoring great performances in business. PAREXEL was recognized for helping its global client base increase the efficiency of clinical trials, access emerging markets, and speed new medical treatments to patients.
PAREXEL was selected as Company of the Year for the Pharmaceutical Industry by an independent panel of internationally-based judges. The Company was honored for transforming its business to deliver best-practice strategic partnering models that leverage its global resources and worldwide technology infrastructure. PAREXEL, which announced strategic partnerships over the past year with Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck, and Pfizer, was recognized for its leadership in bringing more effectiveness to biopharmaceutical development.
"We are honored to be recognized by the judges of The International Business Awards. This award is a tribute to the expertise of our employees who provide innovative solutions to help our clients accomplish their product development goals. We share a vision with our clients to bring healthcare improvements to patients around the world. All of us at PAREXEL are committed to advancing the success of the biopharmaceutical industry in our mission to prevent and cure disease," said Josef von Rickenbach, Chairman and Chief Executive Officer of PAREXEL International.
In addition to the recognition of Company of the Year for the Pharmaceutical Industry, the DataLabs® EDC solution from Perceptive Informatics, a subsidiary of PAREXEL, was named in The International Business Awards as Distinguished Honoree in the category of "Best New Product or Service of the Year: Computer Software – Software as a Service." This honor recognizes the Company's focus on innovation and continuous investment in the next generation of technologies to accelerate clinical development.
Winners and honorees of The International Business Awards, selected from over 3,000 entries received from organizations and individuals in more than 40 countries, were determined through two rounds of judging by close to 200 professionals worldwide. More information about The International Business Awards can be found at www.stevieawards.com/iba.
About The Stevie Awards
Stevie Awards are conferred in four programs: The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.stevieawards.com.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $15 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
SOURCE PAREXEL International Corporation